Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.7000
+0.00851.23%
Post-market: 0.6804-0.0196-2.80%19:59 EDT
Volume:317.73K
Turnover:230.02K
Market Cap:2.95M
PE:-0.04
High:0.7749
Open:0.7400
Low:0.7000
Close:0.6915
52wk High:20.33
52wk Low:0.6141
Shares:4.22M
Float Shares:4.11M
Volume Ratio:0.29
T/O Rate:7.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-19.8182
EPS(LYR):-30.8884
ROE:-3138.91%
ROA:-95.42%
PB:-0.49
PE(LYR):-0.02

Loading ...

BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer

Reuters
·
Mar 02

AIM ImmunoTech Inc - Signs Agreement With Thermo Fisher for Phase 3 Trial of Ampligen

THOMSON REUTERS
·
Mar 02

Roquefort Therapeutics to buy AO-252 licence, raise £8.5m and move to AIM

TIPRANKS
·
Mar 02

Morgans downgrades Ai-Media Technologies Limited (AIM) to a Hold

TIPRANKS
·
Mar 02

Puma AIM VCT Confirms Updated Share Capital and Voting Rights

TIPRANKS
·
Feb 28

Hargreave Hale AIM VCT Confirms Total Voting Rights at 372.9 Million Shares

TIPRANKS
·
Feb 28

AIM ImmunoTech Rights Offering Subscription Rights Expire March 3, 2026

Reuters
·
Feb 27

Press Release: AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Dow Jones
·
Feb 27

Hargreave Hale AIM VCT Extends Early Bird Discount Ahead of Tax Relief Change

TIPRANKS
·
Feb 27

Alien Metals Issues New Shares After Warrant Exercise, Expands AIM Share Capital

TIPRANKS
·
Feb 26

Puma AIM VCT Expands Share Capital With New Allotment Under Subscription Offer

TIPRANKS
·
Feb 26

Hargreave Hale AIM VCT Cuts Share Count With New Buyback

TIPRANKS
·
Feb 25

AIM ImmunoTech extends subscription period of rights offering

TIPRANKS
·
Feb 25

AIM ImmunoTech extends rights offering subscription period to March 3, 2026

Reuters
·
Feb 25

AIM ImmunoTech Announces Extension of Subscription Period of Its Previously Announced Rights Offering to March 3, 2026

THOMSON REUTERS
·
Feb 25

Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM

TIPRANKS
·
Feb 25

Mercia Asset Management Continues Share Buyback With Further AIM Purchase

TIPRANKS
·
Feb 24

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab

TIPRANKS
·
Feb 23

AIM ImmunoTech Inc. Makes Updated Corporate Presentation Available

Reuters
·
Feb 23

Hargreave Hale AIM VCT Expands Share Capital with New LSE Admissions

TIPRANKS
·
Feb 20